Tariffs Are Driving up Premiums for Small Businesses
Some insurers in the ACA’s small group market are citing tariffs, particularly those affecting prescriptions drugs, as a reason for higher-than-expected premium increases.
View the Latest: Prices
Filter
-
-
Health Policy Resources for Covering the 2020 Elections
News ReleaseAs the 2020 Election Day approaches, many candidates continue to focus on health care issues, including on the public health and economic response to COVID-19, the future of the Affordable Care Act, health care costs and abortion.
-
Webinar: How Might the Pandemic Affect Health Premiums, Utilization, and Outcomes in 2021 and Beyond?
Event Date:EventAs the coronavirus pandemic enters its eighth month, we are still facing uncertainty about what the long-term impact of the crisis will be for the health sector, and for patients. However, the extent to which costs grow, and how the burden is distributed across payers, programs, individuals, outcomes, and geography are still very much unknown.
-
After the COVID-19 Public Health Emergency Ends on May 11, Some Consumers Could Face High Prices for COVID-19 Testing
News ReleaseAfter the public health emergency ends on May 11, private health plans will no longer be required to cover the full cost of COVID-19 tests ordered or administered by a clinician or to reimburse consumers for at-home rapid tests.
-
Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act
Issue BriefThe Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.
-
How Do Prescription Drug Costs in the United States Compare to Other Countries?
FeatureThis chart collection examines what we know about prescription drug spending and use in the U.S. and comparably large and wealthy countries, using data from the Organization for Economic Cooperation and Development (OECD).
-
Half of All Hospitals Have Charity Care Costs That Represent 1.4% or Less of Their Operating Expenses
News ReleaseHalf of hospitals reported that the cost of providing charity care to patients represented 1.4% or less of their operating expenses in 2020, though the rates vary widely from hospital to hospital, a new KFF analysis finds.
-
Analysis: Inconsistencies Within Hospital Price Transparency Data Make Cost Comparisons Difficult
News ReleaseSince 2021, federal law has required hospitals to publicly post information about their standard prices and negotiated discount rates for common health services to encourage consumers to compare prices and to promote competition.
-
COVID-19 Test Prices and Payment Policy
Issue BriefThis analysis examines list prices for COVID-19 testing at the largest hospitals in every state and finds they range widely from $20 to $850. Federal law now requires private insurers to cover COVID-19 tests at no cost to the patient and provides funding for people without health insurance.
-
Price Transparency and Price Variation in U.S. Health Services
Issue BriefA new Peterson-KFF analysis examines the potential impact of new federal price transparency rules on patient decision-making and market pricing for health services. The brief also includes new analysis of geographic variation in health prices.